Shots:
- Repare has out-licensed its discovery platform incl. SNIPRx, SNIPRx-surf, & STEP2 , along with certain intellectual property to DCx
- As per the deal, Repare will get $4M as upfront & near-term payments, 9.99% equity in DCx with dilution protection, & future potential out-licensing, clinical & commercial milestones, with low-single digit tiered sales royalties; Repare will also get a board nominee seat in DCx
- Under the deal, DCx will retain ~20 Repare’s staff & acquire lease rights to certain laboratory facilities in Montreal, plus acquire certain laboratory equipment
Ref: Repare Therapeutics | Image: Repare Therapeutics & DCx Biotherapeutics
Related News:- Repare Therapeutics Reports the P-I (MYTHIC) Trial Data of Lunresertib Plus Camonsertib to Treat Gynecologic Cancers
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
